1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Biological Therapies for Cancer: Technologies and Global Markets

REPORT HIGHLIGHTS

The global market for biologic cancer treatment totaled about $51.2 billion in 2014 and is expected to reach $66.4 billion in 2019, registering a compound annual growth rate (CAGR) of 5.4% for the period 2014-2019.
This report provides:
An overview of the global markets and technologies for biological therapies for cancer
Analyses of global market trends, with data from 2013 and 2014, and projections of compound annual growth rates (CAGRs) through 2019.
Detailed analyses of products in the market, market structure and competitive environments, cancer markets in newly emerging therapeutics, and analysis of biosimilars and their impact on the market.
Details concerning the strengths, weaknesses, opportunities, and threats facing various cancer biotherapeutics already on the market.
A look at major issues involved in the research and development (R&D) of more effective cancer therapeutics, and new cancer therapeutics in development and in clinical trials.
Comprehensive profiles of major players in the cancer biotherapeutics field.

SCOPE AND FORMAT

This report provides an update on BIO048B Biological Therapies for Cancer: Technologies and Global Markets. It reviews global markets for biologic therapeutics for cancer and forecasts trends for the use of biologics and cancer treatments through 2019. It discusses important biologics, market share by cancer type, products on the market, market share by company, statistical information for cancer types prevalent globally, with special emphasis on the U.S. market. It also includes current issues and trends affecting the industry, costs and factors influencing demand. The report covers biological products in development, biological products in clinical trials, and currently marketed and late-stage development biologic cancer products.
The market and sales data for various years gives strong support for the research and development (R&D) program and the move toward biologic treatment for cancer, as well as within biologic toward human monoclonal antibodies, vaccines and interferons.

The biologic drug classes discussed in this report with special focus on cancer treatment are:

Monoclonal antibodies.
Vaccines.
Erythropoietin.
Colony stimulating factors.
Interleukins and interferons.
The following approaches to cancer therapeutics are excluded in the report:
Chemotherapy.
Alkylating agents.
Antimetabolites.
Cytotoxic agents.
Plant derivatives and hormone therapy corticosteroids.
Hormone antagonists/antagonists aromatase inhibitors.
Radiation therapy.
Adjunctive therapy.
Biological therapies for treatment of other diseases will not be addressed in this report.

The report also covers biological products in development, biological products in clinical trials, and currently marketed and late-stage development biologic cancer products, including:
Treatment trends and sales patterns across major cancer indications for Japan, Europe E.U.5 nations (i.e., France, Germany, Italy, Spain, the U.K.), the U.S. and the rest of the world (ROW).
Market performance of major pharmaceutical companies.
Forecast sales of leading products across major indications to 2019.
Biosimilars and their impact on currently marketed cancer biotherapeutics.

Table Of Contents

Biological Therapies for Cancer: Technologies and Global Markets

Chapter- 1: INTRODUCTION - Complimentary 3

STUDY GOALS AND OBJECTIVES
REASONS FOR DOING THE STUDY
SCOPE AND FORMAT
INTENDED AUDIENCE
METHODOLOGY
RELATED BCC RESEARCH REPORTS
ANALYST'S CREDENTIALS
BCC RESEARCH WEBSITE
DISCLAIMER

Chapter- 2: SUMMARY 2

Table Summary : GLOBAL BIOLOGICAL CANCER TREATMENT MARKET BY SEGMENT, THROUGH 2019
Figure Summary : GLOBAL BIOLOGICAL CANCER TREATMENT MARKET BY SEGMENT, 2008-2019

Chapter- 3: BIOLOGICAL TREATMENTS FOR CANCER 6

DEFINING CANCER
CAUSES OF CANCER GROWTH
CANCER TREATMENT STRATEGIES

Chapter- 4: CANCER DESCRIPTIONS 92

LUNG CANCER
BLADDER CANCER
BREAST CANCER
CERVICAL CANCER
COLORECTAL CANCER
SMALL INTESTINE CANCER
ESOPHAGEAL CANCER
KIDNEY CANCER
LEUKEMIA
LYMPHOMA
LIVER CANCER
MELANOMA
MULTIPLE MYELOMA
BRAIN CANCER
OVARIAN CANCER
PANCREATIC CANCER
PROSTATE CANCER
STOMACH CANCER
HEAD AND NECK CANCERS
Table 1 : MAIN CANCER CATEGORIES

Chapter- 5: PRODUCT SEGMENTS AND TECHNOLOGY 44

MONOCLONAL ANTIBODIES
INTERFERONS
VACCINES
GRANULOCYTE COLONY STIMULATING FACTOR
BIOSIMILARS
OTHER BIOTHERAPY AND GENE THERAPY
Table 9 : GLOBAL BIOLOGICAL CANCER TREATMENT MARKET BY REGION, THROUGH 2019
Figure 1 : GLOBAL BIOLOGICAL CANCER TREATMENT MARKET BY REGION, 2008-2019

Chapter- 6: MARKET DYNAMICS AND OVERVIEW 33

PIPELINE BIOLOGICS
GLOBAL CANCER MARKET TRENDS
GLOBAL ONCOLOGY MARKET
GLOBAL CANCER BIOLOGICAL THERAPEUTIC MARKET
NEW DEVELOPMENTS
CANCER VACCINES
ISSUES AND TRENDS AFFECTING THE MARKET
Table 18 : GLOBAL BIOLOGICS SALES, 2013

Chapter- 7: PRODUCTS IN DEVELOPMENT 33

RECENT DEVELOPMENTS AND APPROVALS
NEW DRUGS AND COMPANIES IN DEVELOPMENT
CLINICAL TRIALS
PIPELINE DRUGS IN DEVELOPMENT
CLINICAL TRIALS IN ONCOLOGY
CONCLUSIONS

Chapter- 8: ONCOLOGY DRUG MARKET 23

MARKET SIZE AND GROWTH
ONCOLOGY MARKET AND GROWTH

Chapter- 9: GLOBAL CANCER STATISTICS 40

GLOBAL CANCER INCIDENCE
CANCER TRENDS
CURRENT CANCER TRENDS AND ECONOMIC BURDEN

Chapter- 10: BIOLOGIC CANCER MARKET ISSUES AND TRENDS 48

MEDICARE AND HEALTHCARE POLICIES
CANCER COSTS
GLOBAL TRENDS
BIOSIMILARS
VENTURE CAPITAL AND RESEARCH INVESTMENT
CONCLUSION

Chapter- 11: COMPANY PROFILES 20

BIOLOGIC COMPANIES
SELECTED COMPANIES AND PROFILES

Chapter- 12: REFERENCES 2

List of Tables

Summary Table : GLOBAL BIOLOGICAL CANCER TREATMENT MARKET BY SEGMENT, THROUGH 2019
Table 1 : MAIN CANCER CATEGORIES
Table 2 : APPROVED RENAL CELL CANCER DRUGS
Table 3 : MONOCLONAL ANTIBODIES FOR NON-HODGKIN'S LYMPHOMA TREATMENT
Table 4 : BRAIN TUMOR SPECIFIC STATISTICS
Table 5 : ASTROCYTOMAS
Table 6 : STOMACH CANCER TYPES
Table 7 : ADENOCARCINOMA STOMACH CANCER STAGES
Table 8 : HEAD AND NECK CANCER TYPES
Table 9 : GLOBAL BIOLOGICAL CANCER TREATMENT MARKET BY REGION, THROUGH 2019
Table 10 : MONOCLONAL ANTIBODIES FOR CANCER TREATMENT
Table 11 : ANTIBODY-BASED DEVELOPMENTS WITH EPITHELIAL CELL-ADHESION MOLECULE
Table 12 : GLOBAL BEST-SELLING MONOCLONAL ANTIBODIES FOR CANCER, 2014
Table 13 : U.S. BEST-SELLING MONOCLONAL ANTIBODIES FOR CANCER, 2007-2009
Table 14 : ERBITUX APPROVALS
Table 15 : GLOBAL BEST-SELLING INTERFERONS FOR CANCER, 2013 AND 2014
Table 16 : GLOBAL BEST-SELLING PREVENTATIVE VACCINES FOR CANCER, 2013 AND 2014
Table 17 : GLOBAL BEST-SELLING SUPPORTIVE CARE DRUGS, 2013 AND 2014
Table 18 : GLOBAL BIOLOGICS SALES, 2013
Table 19 : GLOBAL CANCER INCIDENCE AND FORECAST BY REGION, 2007-2030
Table 20 : GLOBAL CANCER-RELATED DEATHS AND FORECAST BY REGION, 2007-2030
Table 21 : APPROVED ONCOLOGY DRUGS, 2013-2014
Table 22 : GLOBAL ONCOLOGY MARKET BY REGION, THROUGH 2019
Table 23 : GLOBAL ONCOLOGY SALES, 2012 AND 2013
Table 24 : ASIA-PACIFIC SOLID TUMOR MARKET, THROUGH 2019
Table 25 : ASIA-PACIFIC ONCOLOGY MARKET, 2008
Table 26 : GLOBAL BIOTHERAPEUTIC SALES COMPARED TO TOTAL PRESCRIPTION DRUG SALES, THROUGH 2019
Table 27 : U.S. BIOLOGIC DRUG SALES, 2011 AND 2012
Table 28 : GLOBAL BIOLOGICAL MONOCLONAL, ANTIBODY CANCER TREATMENT MARKET, THROUGH 2019
Table 29 : CANCER MONOCLONAL ANTIBODY THERAPIES
Table 30 : GLOBAL BIOLOGICAL INTERFERON/INTERLEUKIN CANCER TREATMENT MARKET, THROUGH 2019
Table 31 : SELECTED INTERFERON DRUG SALES, 2009
Table 32 : PATENT EXPIRIES
Table 33 : REMICADE SALES, 2012-2014
Table 34 : PROCRIT SALES, 2009 AND 2012
Table 35 : GLOBAL BIOLOGICAL CANCER VACCINE MARKET, THROUGH 2019
Table 36 : GARDASIL SALES, 2012 AND 2013
Table 37 : MYLOTARG SALES, 2009
Table 38 : GLOBAL IMMUNOSTIMULANT MARKET, THROUGH 2019
Table 39 : AMGEN SALES, 2012-2013
Table 40 : APPROVED BIOLOGICS CANCER DRUGS, 2013-2014
Table 41 : PROVENGE'S KEY FEATURES
Table 42 : GERON-SPONSORED CLINICAL TRIALS
Table 43 : ADVAXIS DRUG CANDIDATES
Table 44 : ONCOLYTICS BIOTECH CLINICAL TRIALS
Table 45 : ABBVIE ONCOLOGY PIPELINE
Table 46 : ENROLLING OR COMPLETED CLINICAL STUDIES*
Table 47 : PFIZER ONCOLOGY PIPELINE
Table 48 : ONCOLOGY CLINICAL TRIALS, 2009
Table 49 : APPROVED BIOLOGICS FOR CANCER, 2009
Table 50 : RITUXAN TREATMENT INDICATIONS
Table 51 : DENOSUMAB MARKET, THROUGH 2019
Table 52 : TOP CANCER BIOLOGICS, 2007-2009
Table 53 : ONCOLOGY TREATMENT BY REGION, 2013
Table 54 : U.S. BIOLOGICAL CANCER TREATMENT MARKET BY DRUG CLASS, THROUGH 2019
Table 55 : U.S. BIOLOGICAL CANCER TREATMENT MARKET BY PRODUCT, 2007-2009
Table 56 : CAMPATH SALES, 2007 AND 2008
Table 57 : JAPANESE BIOLOGICAL CANCER TREATMENT MARKET BY DRUG CLASS, THROUGH 2019
Table 58 : JAPANESE BIOLOGICAL CANCER TREATMENT MARKET BY PRODUCT, 2008 AND 2009
Table 59 : EUROPEAN BIOLOGICAL CANCER TREATMENT MARKET BY DRUG CLASS, THROUGH 2019
Table 60 : EUROPEAN BIOLOGICAL CANCER TREATMENT MARKET BY PRODUCT, 2008 AND 2009
Table 61 : ASIA-PACIFIC ONCOLOGY COMPANIES
Table 62 : GLOBAL TOP-SELLING BIOLOGIC DRUGS, 2007-2009
Table 63 : U.S. TOP-SELLING BIOLOGIC DRUGS, 2007-2009
Table 64 : CANCER ESTIMATES, 2012
Table 65 : NEW CANCER CASES DIAGNOSED, 2012*
Table 66 : GLOBAL COMMONLY DIAGNOSED CANCERS, 2012
Table 67 : AGE-STANDARDIZED CANCER RATES, 2012
Table 68 : GLOBAL CANCER INCIDENCE BY TYPE, 2008
Table 69 : GLOBAL CANCER DEATHS BY TYPE, 2008
Table 70 : GLOBAL CANCER DISTRIBUTION BY TYPE, 2009
Table 71 : GLOBAL NEW CANCER CASES BY TYPE AND REGION, 2009
Table 72 : NEW CANCER CASES BY TYPE, 2020
Table 73 : GLOBAL NEW CANCER CASES BY TYPE AND REGION, 2020
Table 74 : AMERICAN CANCER SOCIETY RECOMMENDATIONS FOR CANCER PREVENTION
Table 75 : GLOBAL CANCER INCIDENCE, 2008-2030
Table 76 : GLOBAL DISTRIBUTION OF NEW CANCER CASES BY REGION, 2009
Table 77 : GLOBAL CANCER INCIDENCE AND DEATH BY REGION AND GENDER, 2008
Table 78 : GLOBAL CANCER INCIDENCE BY TYPE, 2007-2012
Table 79 : GLOBAL MORTALITY BY CANCER TYPE, 2012
Table 80 : AMERICAS: CANCER FACTS
Table 81 : U.S. LEADING NEW CANCER CASES, 2014
Table 82 : U.S. LEADING NEW CANCER CASES, 2014
Table 83 : U.S. CANCER INCIDENCE BY TYPE, 2007-2009
Table 84 : U.S. CANCER DEATHS BY TYPE, 2007-2009
Table 85 : MAJOR BIOPHARMACEUTICAL PATENT DATES
Table 86 : GLOBAL CANCER RESEARCH INVESTMENT, 2009
Table 87 : GLOBAL BIOLOGIC DRUG PRESCRIPTION SALES, THROUGH 2014

List of Figures

Summary Figure : GLOBAL BIOLOGICAL CANCER TREATMENT MARKET BY SEGMENT, 2008-2019
Figure 1 : GLOBAL BIOLOGICAL CANCER TREATMENT MARKET BY REGION, 2008-2019
Figure 2 : GLOBAL BEST-SELLING MONOCLONAL ANTIBODIES FOR CANCER, 2014
Figure 3 : U.S. BEST-SELLING MONOCLONAL ANTIBODIES FOR CANCER, 2007-2009
Figure 4 : GLOBAL BEST-SELLING INTERFERONS FOR CANCER, 2013 AND 2014
Figure 5 : GLOBAL BEST-SELLING PREVENTATIVE VACCINES FOR CANCER, 2013 AND 2014
Figure 6 : GLOBAL BEST-SELLING SUPPORTIVE CARE DRUGS, 2013 AND 2014
Figure 7 : GLOBAL CANCER INCIDENCE AND FORECAST BY REGION, 2007-2030
Figure 8 : GLOBAL CANCER-RELATED DEATHS AND FORECAST BY REGION, 2007-2030
Figure 9 : GLOBAL ONCOLOGY MARKET BY REGION, 2008-2019
Figure 10 : ASIA-PACIFIC ONCOLOGY MARKET, 2008
Figure 11 : GLOBAL BIOTHERAPEUTIC SALES COMPARED TO TOTAL PRESCRIPTION DRUG SALES, 2008-2019
Figure 12 : GLOBAL BIOLOGICAL MONOCLONAL ANTIBODY MARKET, 2009-2019
Figure 13 : GLOBAL BIOLOGICAL INTERFERON/INTERLEUKIN CANCER TREATMENT MARKET, 2013-2019
Figure 14 : GLOBAL BIOLOGICAL CANCER VACCINE MARKET, 2009-2019
Figure 15 : GLOBAL IMMUNOSTIMULANT MARKET, 2009-2019
Figure 16 : ONCOLOGY CLINICAL TRIALS, 2009
Figure 17 : TOP CANCER BIOLOGICS, 2007-2009
Figure 18 : U.S. BIOLOGICAL CANCER TREATMENT MARKET BY DRUG CLASS, 2008-2019
Figure 19 : JAPANESE BIOLOGICAL CANCER TREATMENT MARKET BY DRUG CLASS, 2008-2019
Figure 20 : JAPANESE BIOLOGICAL CANCER TREATMENT MARKET BY PRODUCT, 2008 AND 2009
Figure 21 : EUROPEAN BIOLOGICAL CANCER TREATMENT MARKET BY DRUG CLASS, 2008-2019
Figure 22 : GLOBAL TOP-SELLING BIOLOGIC DRUGS, 2007-2009
Figure 23 : U.S. TOP-SELLING BIOLOGIC DRUGS, 2007-2009
Figure 24 : GLOBAL CANCER INCIDENCE, 2008-2030
Figure 25 : GLOBAL DISTRIBUTION OF NEW CANCER CASES BY REGION, 2009
Figure 26 : GLOBAL CANCER INCIDENCE AND DEATH BY REGION AND GENDER, 2008
Figure 27 : GLOBAL CANCER INCIDENCE BY TYPE, 2007-2012
Figure 28 : U.S. CANCER INCIDENCE BY TYPE, 2007-2009
Figure 29 : U.S. CANCER DEATHS BY CANCER TYPE, 2007-2009

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Hematological Cancers: Analytical Tool

Hematological Cancers: Analytical Tool

  • $ 11505
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Lung Cancer: Analytical Tool

Lung Cancer: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Ovarian Cancer: Analytical Tool

August 2016 $ 8096

Renal Cancer: Analytical Tool

August 2016 $ 8096

Bladder Cancer: Analytical Tool

August 2016 $ 8096

Brain Cancer: Analytical Tool

August 2016 $ 8096

Breast Cancer: Analytical Tool

August 2016 $ 8096

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.